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A promising approach for addressing a range of diseases lies in the delivery of functional 
biomacromolecules such as nucleic acids or proteins to cells. Polymers, peptides and the different 
shapes accessible through self-assembly of polymeric and peptidic amphiphiles have been widely 
explored as carriers and as containers for reactions on the nanoscale. These building blocks are 
particularly interesting, because several essential parameters such as physical characteristics, 
conditions for degradation or biocompatibility can be tuned to suit specific requirements. In this review, 
different three-dimensional architectures ranging from dendrimers and hyperbranched molecules to 
micelles, vesicles and nanoparticles assembled from synthetic polymers and peptides are discussed. It is 
focused on their function as a carrier for biologically active macromolecules, highlighting seminal 
examples from the current literature and pointing out the remaining and upcoming challenges in this 
important area of research. 
1. Introduction 
The application of biomacromolecules to supplement or replace 
low molecular weight synthetic drugs is a promising idea to 
tackle a plethora of different diseases. Naturally occurring 
macromolecules such as proteins or nucleic acids can be used to 
treat medical conditions, which has several inherent advantages 
over conventional drugs: they are biocompatible, 
biodegradable, have a very specific function and typically do 
not induce immune responses.1 These therapeutic biomolecules 
can fulfil different functions ranging from vaccination to 
regulatory activities or diagnostics,1,2 while the delivery of 
genes can be applied to treat hereditary diseases.3 However, 
direct administration of these functional biomacromolecules to 
the patient is not feasible as both, nucleic acids and 
proteins/enzymes are prone to degradation and clearance upon 
exposure to bodily fluids. This can significantly reduce their 
efficiency, particularly if degradation occurs before reaching 
the intended target. In addition, biomacromolecules have a low 
capability to pass through biomembranes, which further 
decreases their delivery if penetration into the cell is required. 
Consequently, the functional molecules need to be protected 
from the surrounding environment until delivered to the target. 
Different architectures have been exploited for this purpose, 
ranging from natural, e.g. virus-based carriers to synthetic 
liposomes and peptide-based containers to those composed of 
entirely synthetic polymers. 
 
Scheme 1. Illustration of the four major 3D synthetic architectures used as carriers and nanoreactors: dendrimers/hyperbranched polymers, spherical micelles, 
vesicles and nanoparticles (from left to right). Other shapes are also accessible and used, for simplicity only globular objects are drawn. 
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In recent years, research efforts towards superior carrier 
systems have increasingly focused on designing architectures 
composed of peptides and polymers as they have significant 
advantages over virus-based delivery vectors and liposomes. 
Most importantly, the risk of adverse side effects such as 
infections and immunogenicity can be drastically reduced.4 
Moreover, the mechanic stability is increased and new paths for 
decoration with specific targeting moieties are opened up. 
Hence, in this review the recent advances and upcoming 
challenges for synthetic 3D architectures are discussed. The 
focus is laid on their application as delivery vehicles for 
biomacromolecules as well as nanoreactors and artificial 
organelles, while the delivery of small molecules and joint 
systems is reported elsewhere.5-8 The four predominant 
synthetic architectures, dendrimers and hyperbranched 
polymers, micelles, vesicles and nanoparticles (Scheme 1) are 
introduced and discussed in this review. The carriers differ in 
shape and size, dendrimers/hyberbranched polymers are the 
smallest with diameters in the range of 10-20 nm, while 
micelles, vesicles and nanoparticles are significantly larger with 
diameters ranging from under hundred nm to several hundred 
nm.9 In addition to the protection of encapsulated cargo, these 
carrier architectures fulfil other essential purposes as well. A 
range of different surface chemistries are available for 
decoration of the carrier surfaces in order to mediate the 
interaction with the surrounding environment, e.g. to avoid 
adsorption of blood proteins.10 The large pool of polymers and 
peptides available to generate carriers allows to address several 
important parameters and design the system to suit specific 
needs. The key prerequisites are biocompatibility, high 
encapsulation efficiency, “green” encapsulation (avoidance of 
organic solvents that may interfere with the cargo),11 
conservation of activity, improved cellular uptake and sustained 
release. Past research has shown that it is challenging to 
combine all these properties in one carrier as they are 
influenced by different characteristics and some can even have 
conflicting outcomes. The introduction of positive charges for 
example can facilitate the complexation of negatively charged 
cargo such as nucleic acids or negatively charged proteins,12 
and it can also aid the cellular uptake process through 
interactions with the negatively charged cell membrane.13 
However, depending on ratio and amount, positive charges also 
have a detrimental effect as they are known to be highly 
cytotoxic.14 This example illustrates the trade-off that 
enhancing particular characteristics can have on other 
properties and underlines the importance and delicacy of 
designing carriers for functional biomacromolecules. The 
specifics of the cargo further determine the design of the carrier 
architecture. Individual loading strategies are required for DNA 
and siRNA/mRNA due to their difference in negative change 
density. Moreover, they have different intracellular destinations 
(nuclei and cytosol respectively), which necessitates distinct 
prerequisites to be considered during the design of a suitable 
nanocarrier. In this review, recent examples of successful 
carriers that combine some of the most important parameters 
are discussed.  
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The different carrier structures based on synthetic and natural 
polymers are introduced and their performance is evaluated. 
Moreover, the exciting application of these polymeric 
architectures as containers for enzymatic reactions on the 
nanoscale and very recently as artificial organelles is 
highlighted. 
In nanoreactor applications a different purpose is served as the 
contents should not be released. Instead, the polymeric 
assembly acts as a container for a functional molecule such as 
an enzyme, which is acting inside the three-dimensional 
assembly. The enzyme is retained while reactants travel in and 
out to enable reactions in the protected environment of a nano-
architecture.15 In a functional artificial organelle, the 
nanoreactor remains active after uptake by cells and fulfils or 
supplements the tasks of naturally occurring organelles.16 The 
qualification of the different carrier types for these applications 
is described and explained on the basis of recently published 
examples.  
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2. Dendrimers and hyperbranched polymers  
Carriers based on dendrimers and hyperbranched polymers are 
composed of a single molecule, other than the self-assembled 
structures discussed in this review, which contain several 
macromolecules. 
Two different synthetic routes are available for the synthesis of 
monodisperse dendrimers, the divergent and the convergent 
method.17 In the former, the dendrimer is formed generation by 
generation starting from the multifunctional core, while the 
latter describes a method were the dendrons are first 
synthesised separately before attachment to a core in the final, 
dendrimer-forming reaction step. Hyperbranched polymers on 
the contrary are typically obtained through polymerisation of 
ABx-type monomers with dual functionality.
18 The main 
advantage is their one-pot synthesis, and despite the 
polydispersity many characteristic properties are shared with 
their perfect counterparts. Owing to their highly branched 
structure, these molecules possess a globular shape. Typically, 
dendrimers and hyperbranched polymers reach up to 15 nm in 
diameter, which makes them well-suited candidates for delivery 
of biomedically relevant molecules.19 The predominantly used 
dendrimers are polyamidoamine (PAMAM), polypropylene 
imine (PPI) and polyethylene imine (PEI), polyglycerol (PG) 
and poly-L-lysine (PLLys), while PG and PEI/PPI are also 
applied as hyperbranched polymers.20 Commercially available 
PAMAM is the most used polymer and PPI received increased 
interest after significant improvements in its synthesis.21,22 
These polymers have their cationic functional groups in 
common except for polyglycerol, which has a branched 
polyether structure without intrinsic cationic charges.23 Instead, 
it contains manifold hydroxyl groups on the surface that can be 
modified to cations used to complex the nucleic acid cargo.24 
Moreover, the dendritic, globular structures contain inner 
cavities that can be explored for encapsulation of guest 
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molecules; a concept that was introduced by Meijer an co-
workers as a ‘dendritic box’.25,26 The cavities in dendrimers of 
higher generation are more closed due to the increased number 
of terminal groups, which form a dense surface layer. 
Consequently, a higher encapsulation efficiency as well as 
extended release times have been reported with small functional 
molecules as guests.27 In addition to the space inside 
dendrimers and hyperbranched polymers, their multivalent 
surface is also available for interactions with 
biomacromolecules. Particularly large cargo such as nucleic 
acids is complexed through superficial functional groups. A 
multitude of functional groups that can be introduced at 
predefined regions, as for example realised in core-shell type 
dendrimers,28 allow to adjust the carrier specifically to the 
requirements of the cargo and thereby optimise the interaction.  
 
Scheme 2. Schematic illustration of the encapsulation of compact guest 
molecules inside the branched polymers (left) and the complexation of large 
nuclear acid cargo via charged superficial functional groups (right). 
2.1 Delivery Applications 
PROTEINS AND ENZYMES. Dendrimers are widely exploited in 
nanomedicine as carriers for small molecule drugs,19 however, 
only very few examples are known to date where dendrimers 
and hyperbranched polymers have been employed to transport 
macromolecules in their cavity. Yet, the feasibility of this 
concept was shown in a recent publication where a small 
enzyme, lysozyme, was successfully entrapped in a PAMAM-
chitosan core-shell dendrimer. The contained enzyme was 
inhibited and only regained enzymatic activity after release into 
the acidic intracellular environment.29 It is presumed that 
research activities in this direction are hindered by the 
comparably small size of the cavities inside these polymeric 
carriers.  
NUCLEIC ACIDS. The delivery of nucleic acids with dendrimers 
is a very active and prominent area of current research. Here, 
the dimensions of the cavity are not limiting, because DNA and 
RNA are complexed to the outer surface of the polymeric 
carriers. Both, synthetic polymers and peptidic dendrimers 
based on polylysine are explored and allow successful 
complexation and transfection of nucleic acids.30-32 These 
complexes are tightly packed due to strong electrostatic 
interactions between the comparably rigid dendrimers and 
nucleic acids.30 In addition, theoretical simulations revealed 
that with stronger electrostatic interactions, the negatively 
charged cargo is increasingly dehydrated.34 This is in line with 
reports that describe alterations of the tertiary and secondary 
structure of nucleic acids during complexation.33 In addition to 
the overall chemical structure of the polymeric carrier, the 
surface functional groups in particular can affect its 
performance. It was determined for PPI and PEI, which have 
basic amine groups on surface and acidic ammonium groups in 
their interior, that only the superficial groups interact with 
DNA.35 Similarly, the cationic charge of PAMAM dendrimers 
can facilitate the complex formation due to electrostatic 
interactions with the negatively charged backbone of nucleic 
acids.36,37 Consequently, different polymers have been 
functionalised with amines for complexation and delivery of 
nucleic acids.38 Other modifications include decoration of the 
surface with dextrans,39 PEG40 or peptides41 and amino 
acids42,43 and even several different functional groups on 
separate dendrons.44 All these modifications are made in order 
to improve cellular uptake, the complex stability and 
biocompatibility. In addition to the chemical structure and 
surface functional groups, other parameters of the polymeric 
carrier such as the degree of branching or the molecular weight 
can also influence the performance of the carrier system. It has 
been reported that an increase of the degree of branching also 
leads to an increase in relative gene expression,3 which 
correlates well with the observation that branched carrier 
structures are superior to linear polymers.30 Studies comparing 
the performance of linear and hyperbranched/dendritic 
polymers revealed a higher stability against degradation of the 
branched analogues, while both types of polymers can be 
uptaken by cells efficiently.31,45 Moreover, it has been 
discovered that PAMAM dendrimers of the fifth generation can 
complex siRNA more efficiently than those of generation four, 
however, in addition to the polymer size the change in amino 
group content also needs to be considered.46 A similar 
correlation was observed between the molecular weight and the 
gene transfection efficiency,47 but the optimal size for a 
particular system depends on the type of cells used.39 Cellular 
uptake of dendritic and hyperbranched carriers is facilitated by 
electrostatic interactions with the cell membrane via 
endocytotic pathways, yet the release of the cargo from the 
carrier and out of the endosome remains an area of active 
research.48,49 Interestingly, an inverse correlation with 
molecular weight has been described for the uptake of 
PEGylated polylysine dendrimers in lungs.50 More commonly, 
the selective uptake of dendrimer-nucleic acids complexes into 
cancer cells is desired, which has been implemented by 
conjugation of targeting moieties such as specific peptide 
sequences to the dendritic or hyperbranched polymeric 
carrier.41,51,52 In addition to complexation of guest molecules, 
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the multivalent surface of hyperbranched polymers and 
dendrimers is also employed to mediate the interaction with 
surrounding environment and to facilitate specific 
interactions.53 Typically, the carrier systems are designed to 
release their nucleic acid cargo as a response to changes in the 
environment after cellular uptake, e.g. the acidic conditions in 
the endosome or the reductive conditions in the cytosol. These 
conditions can induce conformational changes or degradation 
of the carrier and thus permit release of the cargo.29,48,49,54 A 
central prerequisite for pursuing in vivo applications, the 
cytotoxicity, is well-studied for these polymeric carriers. 
Nevertheless, the impact on the cells may require a more 
detailed investigation as it has been shown that PAMAM itself, 
without any complexed nucleic acids, affects the global gene 
expression profile of the target cells.55 In order to circumvent 
such potential side effects, polymers based on natural building 
blocks and polymers that disassemble upon a trigger are being 
investigated.56 These observations illustrate that more research 
is still needed to fully understand all processes involved in gene 
delivery with dendritic polymers as carriers. The central points 
to be addressed include a detailed knowledge of the processes 
after entering the cell and how these can be influenced by 
particular polymer structures. Several different factors can 
influence the complexation and transport of nucleic acids, the 
targeting of specific cells as well as the gene transfection and 
cell viability,55,57 which underlines that the carrier needs to be 
designed to suit a particular system.    
2.2 Nanoreactors 
Dendrimers are widely used as nanoreactors with entrapped 
inorganic catalysts, while their application as biological 
nanoreactors suffers from the same limitation encountered 
when entrapping enzymes for their delivery: the narrow 
dimensions of the inner cavity. Nonetheless, dendrimers have 
been successfully employed in intracellular nanoreactors 
containing small molecules as catalysts.58 In addition, an 
enzymatic nanoreactor was formed with laccase after 
envelopment with linear-dendritic copolymers to improve the 
stability and catalytic acitivity of this oxidative enzyme.59  
 
3. Micelles  
Micelles are nano-sized objects with a hydrophobic core and a 
hydrophilic corona, which can be formed by self-assembly of 
amphiphilic macromolecules in aqueous environment. 
Alternatively, reverse micelles are assembled in organic 
solvents yielding a hydrophilic core and a hydrophobic corona. 
As this review discusses the delivery and protection of cargo in 
aqueous environment, it is focused on micelles with hydrophilic 
exterior and the entrapment of biomacromolecules. Thus, 
formulations for cancer therapy are excluded and the reader is 
referred to a recently published review on polymeric micelle 
formulations in clinical trials.7  
Micelles are dynamic assemblies, because they are in 
thermodynamic equilibrium with solubilised macromolecule 
chains. The assemblies are stable above the critical micellar 
concentration (CMC), which strongly depends on the properties 
of the macromolecule and the chemical environment of the 
micelles. This dynamic nature of micelles calls for stabilising 
strategies to prevent chain abstraction or carrier dissolution 
upon dilution or exposure to physiological environments such 
as blood. Stabilisation can be achieved by addition of cross-
linking molecules after the self-assembly process to covalently 
link building blocks in the corona or in the core. Various 
crosslinking methods can be applied, such as EDC/NHS 
coupling, azide alkyne click reactions, disulfide bond 
formation, thiolene or thiolyne click reactions, UV induced 
methacrylate crosslinking or maleimidethiol coupling. Ion 
complexation is a non-covalent alternative for micelle cross-
linking.60 Aside from enhanced stability, cross-linking also 
assures circulation of intact carriers in the organism, however, 
it also impedes efficient cargo release. This can be overcome by 
using stimuli responsive cross linkers or introduce responsive 
moieties in different parts of the micelle building blocks.61,62 
Encapsulation of biomacromolecules in micelles can occur 
before or after the assembly process and is facilitated by 
hydrophobic, hydrophilic or electrostatic interactions as well as 
covalent linking of the cargo molecules to the carrier forming 
amphiphiles (Scheme 3).63 
The densely packed molecules and the lack of a cavity prevent 
the use of micelles as effective nanoreactors for 
biomacromolecules, while they have been successfully 
employed with small molecule catalysts.64-66 Furthermore, 
nearly all biomacromolecules are hydrophilic and consequently 
not suited for entrapment in the hydrophobic interior of a 
micelle.  
 
Scheme 3. Illustration of a typical spherical micelle assembled from amphiphilic 
macromolecules (hydrophobic domain in brown, hydrophilic domain in green). 
Loading of cargo is achieved either pre- (orange sphere) or post-assembly 
(purple nucleic acid helix). 
3.1 Delivery Applications 
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PROTEINS AND ENZYMES. Delivery of hydrophobic proteins via 
micelles plays a major role in development of novel 
immunisation strategies, substitution of enzymes in case of a 
deficiency and administration of hormones such as insulin.67 A 
polymer based, antigen presenting micelle for active 
immunisation was prepared by entrapping ovalbumin (ova) 
inside micelles composed of a mixture of poly(ethylene glycol)-
b-poly(propylene sulfide) (PEG-b-PPS) with PEG-b-PPS-
antigen. In mice immunisation studies, the micelles 
administered in combination with the adjuvant CpG induced a 
2.4 fold increase of ova specific CD8+ T-cells in blood and a 
1.7 fold increase in interferon gamma (INF-γ) levels.68 A 
polymer-peptide based micelle assembled from poly(ethylene 
glycol)-b-poly(L-lysine)-b-poly(L-leucine) (PEG-b-PLLys-b-
PLLeu) was subsequently loaded with ova and also applied for 
mice immunisation studies. These micelles with a diameter of 
circa 100 nm caused a 70 to 90-fold increase of IgG levels 
compared to the levels observed for immunisation with free 
ova. However, compared to ova adsorbed to aluminium 
hydroxide gel (alum, an approved adjuvant for human vaccines) 
only a 2-fold increase was reported.69 These studies 
demonstrate that micellar assemblies can be used as antigen 
presenting systems successfully, but still depend on the use of 
adjuvants to trigger the desired immune response. Further, the 
second example illustrates how important the comparison with 
existing vaccination strategies is, since a two fold increase in 
IgG levels hardly justifies the propagation of such complex 
systems. The zwitterionic nature of proteins was exploited to 
enable efficient micelle loading. Haemoglobin (HB) was 
conjugated to the carboxylic acid side chains of a 
poly(ethylene glycol)-b-poly(deprotected 5-methyl-5-benzyl-
oxycarbonyl-1,3-dioxan-2-one)-b-poly(lactic acid) PEG-b-
PMCC-b-PLA polymer.  Depending on the composition of the 
triblock copolymer and the charge state of HB, the 
internalisation of the protein into the micellar core was 
achieved and the cargo was protected.70 
NUCLEIC ACIDS. Delivery of nucleic acids is mainly desired for 
gene therapy applications using circular DNA or for gene 
silencing by short interfering ribonucleic acids (siRNAs). An 
overview of recent advances in the field of nucleic acid delivery 
and suitable polymeric materials, synthesised by RAFT 
polymerisation, can be found elsewhere.71-73 Initial designs of 
micellar carriers for nucleic acid delivery were mainly based on 
condensation of the nucleic acid with cationic polymers such as 
chitosan, poly-L-lysine (PLLys) or polyethylenimine (PEI). 
While these polymers show excellent condensation properties, 
they were found to be highly cytotoxic in vitro and bind non-
specifically to blood serum components in vivo. Micelles 
assembled from a mixture of polycaprolactone-b-polyethylene 
glycol (PCL-b-PEG) and polycaprolactone-b-
polydimethylethylamine (PCL-b-PDMAEMA) were loaded 
with siRNA after their assembly. The PEG block was shown to 
partially shield the positive charges of the PDMAEMA block, 
thereby counteracting the cytotoxic effect observed for cationic 
polymers like PLLys or PEI.74 However, PEG shielding only 
slightly reduces the cytotoxicity of polymers used for nucleic 
acid condensation, cytotoxicity remains a challenge for future 
polymer designs.74 Micelles assembled from 
polydimethylethylamine-b-(polydimethylethylamine meth-
acrylate-co-butylmethacrylate-co-propylacrylic acid) 
(PDMAEMA-b-[PDMAEMA-co-BMA-co-PAA]) polymers 
served both for cationic siRNA binding and terminal biotin-
streptavidin coupling used in a targeting approach. Here, a 
70 % reduction of gene expression in targeted cells was 
obtained.75 In another study, thiol-modified siRNA was coupled 
directly to a copolymer composed of hydroxypropyl 
methacrylate, 2-pyridin-2-yldisulfanyl) ethyl methacrylamide, 
polyacrylic acid, dimethylethylamine methacrylate and butyl 
methacrylate ([HPMA-co-PDSMA]-b-[PAA-co-DMAEMA-co-
BMA]) containing two thiol-disulfide exchange moieties per 
polymer chain. The resulting self-assembled micelles showed 
low cytotoxicity, 90 % mRNA knockdown and 65 % protein 
knockdown.76 Even though these carriers were not tested in 
vivo, the use of PDMAEMA instead of PLLys is a promising 
approach to overcome cytotoxic effects and still allow for 
nucleic acid binding and successful gene silencing. Despite the 
results summarised here, there is still no carrier exhibiting the 
necessary cytotoxicity profiles and a satisfying delivering 
efficacy. Novel synthetic approaches enable the creation of 
various 3D micellar assemblies as well as multi-compartment 
structures.77 As reviewed elsewhere,78 shape, size and 
morphology of the 3D assemblies are key features when 
designing successful carriers.   
 
4. Vesicles 
Polymer vesicles or polymersomes - as they were first named in 
199979 - are micro- or nanosized, spherical and hollow 3D 
architectures. An aqueous solution is enclosed by a membrane 
composed of amphiphilic block copolymers (Scheme 4).80  
 
Scheme 4. Schematic illustration of a synthetic vesicle (top) showing the 
possibility of entrapping biomacromolecules and its application as a nanocarrier 
(bottom, left and right) or as a nanoreactor (bottom, middle). These structures 
can be obtained by the self-assembly in aqueous solutions of amphiphilic block-
copolymers, amphiphipilic oligopeptides or oppositely charged macromolecules. 
Page 6 of 15Biomaterials Science
Journal Name ARTICLE 
This journal is © The Royal Society of Chemistry 2012 J. Name., 2012, 00, 1-3 | 7  
These structures are similar to liposomes (lipid-based vesicles), 
but possess a membrane composed of higher molecular weight 
species, which improves the stability to external stress factors 
such as mechanical shear forces.81 Important parameters 
affecting the formation of polymer vesicles are the critical 
micellar concentration (CMC) and the volume ratio of the 
hydrophilic to hydrophobic block of the amphiphilic 
copolymer. The self-assembly process is strongly influenced by 
the equilibrium between the free energy contributions to the 
self-assembly and kinetic factors.82,83 Hence, introduction of 
additional blocks or variation of the block lengths induces 
morphological changes of the final vesicular structures 
(Figure 1).84 Two general methods are known for polymersome 
preparation and they differ in their use or avoidance of organic 
solvents.85 The block copolymer can either be dissolved in an 
aqueous solution directly (direct dissolution) or via the 
hydration of a pre-casted copolymer film (film rehydration) 
using an aqueous solution under mechanical stirring. In the 
electroformation method, the application of an electrical field 
induces vesicle formation. Organic solvent based methods on 
the other hand involve the use of emulsion templates or 
dissolution of the polymers in a suitable organic solvent, 
followed by the injection of this solution into an aqueous phase 
(co-solvent or the phase inversion technique). It has to be taken 
into account, however, that residual organic solvent can impede 
the functionality of biomacromolecular cargo. Polymersomes 
are particularly attractive because they are able to entrap 
hydrophilic molecules in their inner cavity86 and at the same 
time they can insert hydrophobic compounds in their 
membrane.87 In addition, it is possible to generate hybrid 
polymer and lipid vesicles by alignment of amphiphilic 
compounds (for example lipids) at the hydrophobic-hydrophilic 
interface.88 The membrane of polymersomes is flexible and can 
undergo conformational changes in order to allow insertion of 
membrane proteins.89 Such membrane proteins serve as gates 
for transfer of products/substrate between the inner cavity and 
the surrounding environment of the vesicles. The release of 
encapsulated cargo can be achieved by degradation90  or by 
conformational changes91 when using stimuli-responsive block 
copolymers. Importantly, polymersomes designed to be used as 
nanoreactors or even artificial organelles need to be stable for 
long time periods upon internalisation in cells. To date, a 
maximum of 48 hours stability has been reported for artificial 
peroxisomes.92 Depending on the specific application as 
conventional drug delivery system, as nanoreactors or as 
artificial organelles, polymersomes have to fulfil different 
requirements regarding their stability, membrane permeability, 
biocompatibility and flexibility.  
4.1 Delivery applications 
PROTEINS AND ENZYMES. Polymersomes are applied as 
protective 3D architectures when used as protein carriers. They 
can maintain structural integrity and proteins contained in the 
aqueous cavity retain their activity. Importantly, high protein 
loading efficiencies ranging from approximately 60 to 100% 
have been reported for the encapsulation of bovine serum 
albumin (BSA), cytochrome C (CC), lysozyme (Lys), and 
ovalbumin (OVA) in biodegradable polymersomes composed 
of poly(ethyleneglycol)-b-poly(ε-caprolactone)-b-poly(2-
(diethylamino) ethyl methacrylate) (PEG-b-PCL-b-PDEA) 
triblock copolymers93 and poly(ethylene glycol)-b-poly(acrylic 
acid)-b-poly(N-isopropylacrylamide) (PEG-b-PAA-b-
PNIPAM) triblock copolymers crosslinked with cysteamine.94 
Further, antibody delivery has been realised using polymer 
vesicles self-assembled from a diblock copolymer with a 
biocompatible poly[2-(methacryloyloxy)ethyl 
phosphorylcholine] (PMPC) domain and a pH-sensitive poly[2-
(diisopropylamino)ethyl methacrylate] (PDPA) domain.95 
Additionally, immunoglobulin G (IgG) has been encapsulated 
at a high loading capacity of 89.6% in PEG-b-PCL-b-PDEA 
vesicles.93 PEG linked to a pH sensitive PDEA block 
(pKa ≈ 7.2 in water) generated vesicles for encapsulation and 
release upon a dual release route (reduction or pH change) of 
BSA and CC.96 Release upon exposure to oxidative conditions 
was facilitated by polymersomes based on poly(propylene 
sulfide) (PPS) and poly(ethylene glycol) (PEG), which 
contained encapsulated OVA.97 These examples reveal that the 
encapsulation of proteins is a function of the chemical structure 
of the copolymers and thus the properties of the membrane. 
Systems responding to a variety of stimuli including pH,93,95,96 
temperature,94 reductive94,96 or oxidative environment97 have 
been generated. Moreover, the responsiveness can be tuned to 
increase the efficiency of cellular uptake of nanocarriers or to 
avoid endosomal sequestration and degradation.98 
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Figure 1. Examplary TEM images of 3D vesicular nanoarchitectures. The block copolymers used to assemble these structures are composed of glycerol 
monomethacrylate (G), 2-hydroxypropyl methacrylate (H), benzyl methacrylate (B) and ethylene glycol dimethacrylate (E). The top row of TEM micrographs 
represents an overview of the vesicle samples, while the images below provide details of single vesicles. On the left (group A) it is shown that the introduction of an 
additional B block and changing the polymer block length induces conformational changes in the structure. On the left (group B), similar behaviour is observed by 
replacement of the B block with the E block. Futher, the influence of surfactant on the final conformation of the architecture is demonstrated. Adapted with 
permission from Chambon et al.
84
, copyright 2012 of the American Chemical Society. 
An important aspect in the design of 3D assemblies for medical 
applications is the biocompatibility of its components. 
Variations in the preparation conditions (i.e. cross-linking 
density, UV irradiation time, solvent) during polymer vesicle 
formation determine their cytotoxic behaviour as shown for 
poly(ethylene glycol)-b-poly(diethylaminomethacrylate-stat-
poly-3,4-dimethylmaleinimidobutylmethacrylate) (PEG-b-
PDEAMA-s-PDMIBM) and poly(ethylene glycol)-b-
poly(diethylaminomethacrylate-stat-poly-3,4-
dimethylmaleinimidoethylmethacrylate) (PEG-b-PDEAMA-s-
PDMIEM) poylmersomes.99 Here, long UV irradiation times 
and the presence of phosphate buffer during the vesicle 
preparation might induce formation of toxic byproducts.  
NUCLEIC ACIDS. Polymersomes are carrier systems able to 
deliver hydrophilic and hydrophobic active compounds 
simultaneously. Polymeric vesicles of a pH responsive, 
biodegradable amphiphilic methoxy-poly(ethylene glycol)-b-
poly(lactic acid) (mPEG-b-PLA) copolymer were reported to 
co-deliver B-cell lymphoma-extra large inhibitor (Bcl-xL) - 
siRNA specific (Bcl-xLsiRNA) and hydrophobic doxorubicin 
(DOX).87 Co-loaded polymersomes exhibited a beneficial 
synergic interaction and promising results in all assays 
regarding cytotoxicity, steady release and cell apoptosis. A 
complex copolymer composed of lipopolysaccharide-amine 
(LPSA) with a negatively charged backbone (oxidized sodium 
alginate (OA)) and a hydrophobic side chain (cholesteryl 
(Cho)) linked to another positively charged hydrophilic moiety 
(polyethyleneimine, PEI) was proposed for achieving high 
transfection efficiencies.100 Self assembly of this polymer into 
vesicles was induced by electrostatic interaction of anionic 
enhanced green-fluorescence protein plasmid (pEGFP) with 
cationic PEI. The vesicular membrane was composed of a 
central, hydrophobic Cho block and two hydrophilic OA layers 
surrounded by charged PEI corona. Lysosomal escape of the 
vesicles was facilitated by the positively charged amino groups 
of the PEI block via the proton sponge effect. These 
nanocarriers were able to transfect mesenchymal stem cells 
(MSCs) with an efficiency of 95%. In a related study, tumour 
microenvironments characterised by an acidic nature were 
addressed by pH sensitive polymersomes of di- or triblock 
copolymers consisting of PEG, poly(imidazole-butyl) 
methacrylate and poly(glycidylmethacrylate) blocks.91 Double 
stranded DNA was encapsulated in these vesicles and release of 
their payloads occurred only under specific pH conditions. 
Non-viral vectors based on polymersomes have been shown to 
act as efficient nanocarriers in vitro, but most of these systems 
do not live up to the expectations to accomplish their task in 
vivo. Indeed, polymer vesicles can safely deliver nucleic acids 
into cells, however, the unprotected cargo is unstable after 
release. Therefore, further optimisation is required in terms of 
stability, biocompatibility, and functionality of polymersomes 
as gene delivery vectors with respect of their application in 
vivo. 
4.2 Nanoreactors, artificial organelles and synthetic cells 
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Recently, polymer vesicles have been proposed as 
compartments for reactions ranging from nanoreactors101 to 
artificial organelles92,102,103 and cell mimics104 (Figure 2). For 
applications as nanoreactors, the vesicles need to be highly 
stable for prolonged time periods, as opposed to their 
application as conventional drug delivery systems, where their 
cargo is released. In this respect, the vesicle membrane needs to 
be permeable to substrates/products of reactions occurring in 
the inner cavity. Permeability of the membrane can be 
generated by different approaches: a specific chemical nature of 
amphiphilic copolymers105-107 or chemical modification of the 
membrane after vesicle formation108,109 or insertion of channel 
proteins inside synthetic membrane.101,110-113   
Several model systems have shown the potential of vesicular 
nanoreactors. In addition to single enzyme type 
nanoreactors,103,113,114 entrapped combinations of enzymes 
participating in reactions have been described.115,116 
Haemoglobin was encapsulated in vesicles assembled from 
poly-(2-methyloxazoline)-b-poly(dimethylsiloxane)-b-poly(2-
methyl-oxazoline) (PMOXA-b-PDMS-b-PMOXA) triblock 
copolymers, where it fulfilled a dual role. Haemoglobin 
detoxified peroxynitrites present in the vesicular environment 
and stores oxygen.117 Nanoreactors with triggered activity were 
introduced by encapsulation of Rose Bengal - bovine serum 
albumin conjugate (RB–BSA) inside polymersomes composed 
of PMOXA-b-PDMS-b-PMOXA. This membrane is permeable 
to oxygen, enabling the nanoreactors to release reactive oxygen 
species (ROS) “on demand”, thereby promoting cellular 
toxicity at predetermined time and location.118 Moreover, 
thymidine phosphorylase encapsulated in polymersomes of the 
same triblock copolymer maintained stability in blood serum 
for several days with only a slight decrease in enzyme activity 
over time.119 Interestingly, an increase of catalytic activity after 
enzyme encapsulation was reported for trypsin in polystyrene-
b-poly(acrylic acid) (PS-b-PAA) block copolymer (BCP) 
vesicles.120 Successful nanoreactors were also formed with 
trypanosomavivax nucleoside hydrolase in PMOXA-b-PDMS-
b-PMOXA vesicles, which can be applied in enzyme 
replacement therapy121 and by entrapment of β-lactamase in 
similar vesicles used for hydrolysis of antibiotics.101  
 
 Figure 2. Typical applications of polymersomes as a nanoreactors (left, reproduced with permission from ref. 158), as an artificial peroxisome (centre, adapted with 
permission from ref. 92, copyright 2013 American Chemical Society) and as a cell mimic (right, adapted with permission from ref. 104). 
A three-enzyme cascade reaction system has been developed by 
the encapsulation of glucose oxidase (GOx) in the inner cavity, 
insertion of Candida Antarctica lipase B (CalB) in the bilayer 
membrane and immobilisation of horseradish peroxidise (HRP) 
on the surface of polystyrene-b-poly(l-isocyanoalanine(2-
thiophen-3-yl-ethyl)amide) (PS-b-PIAT) copolymer vesicles.115 
Recently, research activities extended to the formation of 
artificial organelles, which represent nanoreactors that are 
uptaken and active inside cells. The first example of an 
artificial organelle mimicking natural peroxisomes was realised 
by co-encapsulation of antioxidant enzymes (Cu/Zn SOD, and 
lactoperoxidase, LPO, or catalase, CAT) in polymersomes 
(Figure 2 centre).92 These enzymes are the main proteins inside 
peroxisomes and indeed, upon uptake in HeLa cells, the 
enzymes acted in tandem inside the artificial peroxisomes and 
allowed simultaneous detection and detoxification of  reactive 
oxygen species (ROS). Moreover, an approach to mimic 
eukaryotic cells was recently described. Here, a polymersome-
in-polymersome system is used to perform cascade reactions 
across multiple compartments (Figure 2 right). First, individual 
enzymes such as Candida antarctica lipase B (CalB), alcalase 
and alcohol dehydrogenase (ADH) were encapsulated in 
polystyrene-b-poly(3-(isocyano-lalanyl-aminoethyl)thiophene) 
(PS-b-PIAT) polymersomes with sizes ranging from 180 to 300 
nm.104 Subsequently, these vesicles were encapsulated in 
micrometer sized polybutadiene-b-poly(ethylene oxide) (PB-b-
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PEO) polymersomes together with free enzymes and reagents. 
This design provides a protected environment for the enzymes. 
The reactions are initiated once reactants and products diffuse 
across the inner polymersomes membrane. An initial 
profluorescent substrate undergoes a multi-step, enzyme-
catalysed reaction to yield resorufin as a final, fluorescent 
product.  
Further research and optimisation of artificial organelles and 
polymersome-in-polymersome systems is needed, particularly 
towards improvements of the encapsulation efficiency (of 
biomacromolecules and also small polymersomes), cell uptake 
and addressing specific pathologic conditions. An additional 
challenge is the enhancement of mechanical stability of 
polymersomes after internalisation in cells. The current 
examples show a promising and elegant way to assemble 
complex systems and gain a deeper understanding of the 
involved biological processes. Nevertheless, there are still a 
several issues to be addressed until advanced mimics of cells 
can be obtained. The ability of polymer vesicles to self-
replicate for example or their capability to mimic processes that 
can be switched on and off - like in the living cell - are some 
interesting challenges to be investigated in the future.122 
4.3 Special vesicular architectures 
POLYION COMPLEX VESICLES (PICSOMES). Analogous to 
amphiphilic molecular assemblies, 3D architectures can be 
obtained by mixing macromolecules of opposite charges. In 
particular, self-assembly of oppositely charged diblock 
copolymers driven by electrostatic interactions leads to 
nanosized hollow vesicles referred to as PICsomes or PIC 
vesicles. Diblock copolymers made of polyethylene glycol 
(PEG) and charged poly(amino acid)s can form ion pairs 
(interaction between primary amino groups on the polycation 
and carboxylic acid moieties on the polyanion). Therefore, 
these structures spontaneously self-assemble in aqueous media 
under neutralisation of the charges, forming a closed 
semipermeable polyion complex (PIC) membrane. Importantly, 
organic solvents can be avoided during the preparation of such 
polymersomes.123 The membrane of polyion complex vesicles 
is permeable to small molecules and ions, but 
biomacromolecules cannot permeate the membrane and can 
therefore be successfully encapsulated.124 To date, only 
myoglobin-loaded PICsomes were demonstrated as a carrier 
system for use in medical applications.125 This field is just 
beginning to develop and thus the formation and efficiency of 
PICsomes as carriers or even nanoreactors has to be 
demonstrated for a broader applicability in the future. 
PEPTIDE-BASED VESICLES. Peptosomes are a special class of 
polymersomes, as they are based on oligopeptides rather than 
synthetic polymers.126,127 Self-assembly in aqueous solution 
induces formation of vesicles with a diameter of around 50-
90 nm, as reported for very short peptides (≈ 2 nm) composed 
of aspartic acid and hydrophobic amino acids128 and 
gramicidin A - poly(ethylene glycol) (PEG) conjugates.129 
These biomimetic vesicles were used to design nanocarriers for 
delivery of proteins. Successful encapsulation was described for 
BSA and insulin, enzymes (lysozyme) and antibodies.130  
Moreover, delivery of nucleic acids to cells has been reported 
using a versatile cationic dipeptide nanotube complexed with 
single-stranded DNA, which rearranged upon dilution into 
vesicular structures.131 Peptosomes are regarded as intrinsically 
biocompatible and biodegradable and have a higher 
biospecificity, which can improve their interaction with tissue 
and cells, underlining their potential as multifunctional delivery 
systems for biomacromolecules.132 
 
5. Nanoparticles  
Polymer and peptide nanoparticles are solid, in most cases 
spherically shaped objects with different morphologies. Most 
commonly multi-compartment micelle (MCM) architectures 
and polyplexes are reported, which are formed by direct 
interaction of the payload with the carrier material (see 
Scheme 5). These self-assembled structures are very promising 
candidates to serve as carriers not only for small molecules but 
also for (bio-) macromolecules. MCMs differ from other nano-
scale delivery systems, they possess similar volume fractions 
for entrapment of hydrophilic and hydrophobic payloads. 
Furthermore, high stability of the nanoparticles is achieved 
owing to their solid character. Integrated release mechanisms, 
stealth coatings and specific targeting moieties have been 
included in the design towards smart and functional 
nanoparticles based carriers. In contrast to the previously 
discussed architectures, which form regardless of their cargo, 
the driving force for polyplex-formation is the physical 
interaction between payload and carrier material. This direct 
interaction of guest molecules with the carrier polymer/peptide 
typically occurs either via charge compensation or by 
entrapment using hydrophobic interactions during nanoparticle 
formation. These nanoparticles can be unimolecular or they can 
be composed of a combination of different molecular species. 
Besides spontaneous degradation, the release of the payloads is 
achieved via stimuli responsiveness of nanoparticles, provided 
they have the appropriate chemical nature. Delivered 
biomacromolecules include enzymes, antigens, proteins, and 
nucleic acids, which are usually condensed using polycationic 
molecules. Moreover, positive ratios of cations to the anionic 
phosphate in nucleic acids (N/P-ratio) favour the adsorption to 
mammalian cell membranes and internalisation is accelerated 
due to ionic interactions with negatively charged cell 
membranes.13  
Functional nanoparticles can be assembled from synthetic 
polymers and/or peptides. Often, amphiphilic or charged 
macromolecules are used to form nanoparticles via self-
assembly. The peptides consist of sequences built from 
naturally occurring amino acids and the predominant synthetic 
polymer is the FDA approved poly(lactic-co-glycolic) acid 
(PLGA) copolymer. Owing to its biocompatibility and 
biodegradability, PLGA is replacing polyethylenimine (PEI), 
which is cytotoxic at high dosage. In addition, biodegradable 
polymers composed of are poly(b-amino ester), poly(a-(4-
aminobutyl)-L-glycolic acid (PAGA) and polyphosphoester are 
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used for generation of nanoparticles.133 An elegant approach to 
induce stimuli-responsiveness is to use polymers and peptides 
containing reductively cleavable groups or pH-sensitive linkers. 
 
Scheme 5. Schematic view of a polyplex and a multicompartmentmicellar 
assembly, both carrying condensed nucleic acids (purple). On the left, a random 
coiled structure derived from properties and interactions of both carrier and 
nucleic acid payload is shown, whereas the architecture on the right consists of 
the well-defined arrangement of micelles driven by the amphiphilicity of their 
carrier material. 
However, to date nanoparticles have not been applied to act as 
nanoreactors, because the intrinsic solid state of nanoparticles 
does not allow proteins or enzymes to act freely inside. Hence, 
nanoparticles are specific 3D assemblies serving only for 
transport and release of the entrapped biomacromolecules. 
5.1 Delivery applications 
PROTEINS AND ENZYMES. Nanoparticles for the delivery of 
proteins and enzymes were mainly formed using the  
emulsification-solvent evaporation method9 or the desolvation 
technique.134 The first method is based on emulsion formation 
followed by sonication and subsequent solvent evaporation. 
Nanoparticle formation via the desolvation technique is induced 
by drop-wise addition of ethanol to an aqueous solution of 
proteins, which can subsequently be stabilised by cross-linking. 
Recently, a “green” method was reported for efficient loading 
of peptidic nanoparticles with model proteins by simple mixing 
of aqueous solutions of carrier and cargo.11 Other studies report 
cross-linked enhanced green fluorescence protein 
nanoparticles135 and a combination of the cell-penetrating and 
enzyme-stabilizing protein 30Kc19 (originating from 
silkworms) with human serum albumin136 as carriers for beta-
galactosidase. Alternatively, polymeric nanoparticles have been 
used for delivery of a variety of biomacromolecules such as 
antigenic peptides137 and proteins,138 tetanus toxoid,139 
insulin,140 ovalbumin,141 influenza hemegglutinin and 
superoxide dismutase.9 
NUCLEIC ACIDS. Nucleic acids are condensed to smaller sizes 
for their delivery using polycations such as polyethylenimine 
(PEI), poly-L-lysine (PLLys), spermidine, histones, and other 
cationic lipids, peptides or polymers. Enhancement of cell 
uptake can be achieved by recognition sequences or specific 
moieties. These can be directly included in the sequence of 
peptides used for nanoparticle formation, while for polymeric 
systems they need to be coupled post-synthesis. Naturally 
occurring cell penetration peptides (CPPs) like RGD, poly-
arginine, MPG, MAP, KALA, pVEC, Tat are often used in this 
respect (Table 1). Many concepts in this area of research are 
inspired by nature, for example a recently published study 
where peptide sequences derived from gramicidin A were used 
to deliver siRNA to the cytosol. The nucleic acid was first 
condensed with a cationic peptide, before peptide beads were 
formed using an uncharged analogue.142  Moreover, successful 
DNA delivery has also been reported with modified pVEC,143 
and KALA peptides modified with an additional RGD cell 
adhesion motif.144 Efficient transfection was obtained using 
peptide amphiphiles bearing both an RGD sequence and an 
octaarginine (R8) cell penetrating peptide.145 In order to 
improve the localisation of nanocarriers, specific targeting to 
LHRH-receptors (usually over-expressed in breast cancer 
cells)146 was achieved with lysine and histidine-rich peptides.147 
pH-triggered release of DNA was facilitated by using 
nanoparticles of carboxymethyl poly-L-histidine (CM-PLH) 
and poly(ß-aminoester). The CM-PLH coating significantly 
decreased the cytotoxicity and at the same time improved the 
specific localisation at tumour sites due to the EPR effect.148 
Dendronized polypeptides, containing histidine, phenylalanine, 
and a backbone bearing disulfide bonds were able to release 
siRNA upon reduction.44 Moreover, KALA peptides decorated 
with RGD-moieties were used to condense DNA. These 
peptides were oligomerised to obtain di-, tri-, and tetramers via 
a disulfide linker during the formation process, which 
subsequently acted as reduction sensitive part of the 
nanoparticles.  
Table 1. Abbreviations and corresponding sequences of some cell penetrating 
peptides often used for enhanced internalisation to cells. Sequences are noted 
according to the mentioned references, length of sequences may differ from 
other literature.  
 Sequence Reference 
RGD RGD 145 
MPG GALFLGFLGAAGSTMGAWSQPKK
KRKV 
149 
MAP KLALKLALKALKAALKLA 
KALA WEAKLAKALAKALAKHLAKALAK
ALKACEA 
pVEC LLIILRRRIRKQAHAHSK 143  
R8 RRRRRRRR 145  
R9 RRRRRRRRR 150 
Tat GRKKRRQRRRPPQ 149 
PTD4 YARAAARQARA 150 
Transportan GWTLNSAGYLLGKINLKALAALAK
KIL 
 
Besides, nucleic acid cargo can also be delivered and released 
from polymeric nanoparticles. Linear cationic click polymers 
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containing disulfide bonds, secondary amine groups and amide-
triazole moieties were reported to deliver and release pDNA in 
a reductive environment, if the DNA had been condensed with 
PEI first.151 Moreover, efficient delivery of nucleic acid 
payload to mesenchymal stem cells, which is of high interest in 
regenerative medicine, was recently reported.71,152 In this study, 
a pH-responsive diblock copolymer composed of 
poly(dimethylaminoethyl methacrylate) (PDMAEMA), 
poly(butyl methacrylate) (PBMA) and poly(propylacrylic acid) 
(PAA) was used to form nanoparticles of siRNA and the 
copolymer. In addition, successful dual gene knockdown in 
ovarian tumours in vivo is described for shRNA condensed with 
PLLys/PLGA nanoparticles.153  
The use of nuclear localisation signals (NLS) is important for 
nuclear delivery of DNA. This was observed for PEI/PLGA 
nanoparticles with covalently attached NF-κB (an NLS), which  
significantly increased the particle delivery.154   
In addition to purely peptidic and purely polymeric systems, 
polymer-protein conjugates can also form nanoparticles and 
deliver pDNA, as shown for example with BSA-
poly(dimethylamino) ethyl methacrylate (PDMA) based 
nanoparticles.155  
To date, a variety of nanoparticles have been developed and 
proved their functionality in vitro. However, only few of them 
also showed applicability in vivo.146,148,151,153,156,157 
 Despite favourable effects on internalisation, positively 
charged nanoparticles tend to agglomerate upon contact with 
serum proteins, leading to accumulation in thin capillaries and 
ultimately cause blockages of the blood stream. Further, a 
balance has to be kept between the several desirable 
requirements for drug delivery systems and the need to reduce 
the complexity of assembled nanoparticles to avoid possible 
sources of error in the statistical preparation process.  
Conclusions 
In this review, the four most prominent architectures that can be 
used to deliver functional biomacromolecules to cells are 
discussed. All carriers are composed of natural or synthetic 
polymers, giving rise to a large pool of different functionalities 
and their combinations. These carriers have been employed to 
transport a variety of different biomacromolecules, ranging 
from enzymes to proteins and nucleic acids. An overview of the 
guest molecules discussed in this review and their 
corresponding carrier architectures is presented in Table 2. This 
data collection shows that nanoparticles and dendrimers are 
preferentially used to transport and deliver nucleic acids, while 
vesicles in particular are predominantly used to carry enzymes. 
In addition to ‘simple’ carriers, we also elucidated the 
application of these 3D architectures as containers for reactions. 
This strategy involves the encapsulation/insertion of active 
compounds (enzymes, proteins, mimics) that are free to act in 
situ, protected by the architecture of the 3D assembly. From 
model nanoreactors to artificial organelles, these systems 
combine the functionality of biomacromolecules with the 
molecular properties of 3D assemblies, such as stability, 
membrane flexibility and permeability or flexibility. However, 
the internalisation of nanocarriers into cells requires more and 
detailed investigations. This often occurs via endocytotic 
pathways, and the detailed mechanisms are not yet fully 
understood. Further hurdles come up during approval process 
of self-assembled systems through public health authorities, 
because the accumulation in the body and long-term toxicity is 
difficult to estimate for completely new 3D assemblies. 
Nevertheless, several exciting and innovative systems have 
been developed and investigated with respect to their behaviour 
in cells or in living organisms. These results are very promising 
and underline that research activities are going towards the 
right direction, but they also outline the potential for 
improvements. We hope that this compilation and the 
remaining challenges to be overcome for each system aid the 
reader with the selection of an appropriate polymeric carrier for 
their desired system.  
Table 2. Summary of the different biomacromolecular guest molecules 
discussed in this review and the types of carriers used to transport them. 
Biomacromolecular 
guest 
Carrier architectures 
siRNA dendrimer,24,40,41,159 micelle,74-76 polymeric 
vesicle,87 multicompartment micelle,142 
polyplex nanoparticle8,44,152,156  
DNA dendrimer,30,32,33,42,43,45,51,52,55 polymeric 
vesicle,91,100 peptidic vesicle,131 peptidic 
nanoparticle,143-145,147,148 polymeric polyplex 
nanoparticle151,154,157,160,161  
alcalase polymeric vesicle104 
alcohol dehydrogenase polymeric vesicle104 
antigenic proteins polymeric nanoparticle8 
beta-galactosidase peptidic nanoparticle135,136  
beta-lactamase polymeric vesicle101  
bovine serum albumin polymeric vesicle93,94,96,130 nanoparticle11,12 
BSA-rose bengal 
conjugate 
polymeric vesicle118 
candidaantarctica lipase 
B 
polymeric vesicle158 
catalase polymeric vesicle162 
Cu/Zn superoxide 
dismutase 
polymeric vesicle,162 
polymeric nanoparticles9  
cytochrome C polymeric vesicle93,94,96  
haemoglobin micelles,61 polymeric vesicles117 
horseradish peroxidase polymeric vesicle158 
glucose oxidase polymeric vesicles115,158  
immunoglubulin G polymeric vesicle,95  peptide vesicle130  
influenzahemagglutinin polymeric nanoparticles9 
insulin micelle,67 peptide vesicles130  
laccase linear-dendritic copolymer59 
lactoperoxidase polymeric vesicles92 
lysozyme dendrimer,29 polymeric vesicles,93,94 peptide 
vesicles130 
myoglobin PICsomes125  
ovalbumin micelles,68,69  polymeric vesicles93,94,97 
polymeric nanoparticles141  
thymidinephosphorylase polymeric vesicles119 
trypanosomavivax 
nucleoside hydrolase 
polymeric vesicles121  
trypsin polymeric vesicles120  
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